<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cardiomyocyte <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:hpo ids='HP_0001635'>heart failure</z:hpo> has been the topic of research in many recent studies </plain></SENT>
<SENT sid="1" pm="."><plain>In the present investigation, the potential cardioprotective effect of gymnemic acid <z:chebi fb="0" ids="16247">phospholipid</z:chebi> complex (GPC) on myocardial <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cardiac function was studied in <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (DOX; 30 mg/kg/ip/single dose)-induced <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> model in rats </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="28748">Doxorubicin</z:chebi> induced <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> was evidenced by significant hemodynamic changes (increased systolic, diastolic, mean arterial pressure and heart rate), <z:mp ids='MP_0002834'>decreased heart weight</z:mp> to body weight ratio, increase in serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) and <z:chebi fb="0" ids="29108">Ca2+</z:chebi> levels and decrease in myocardial <z:chebi fb="1" ids="29101">Na+</z:chebi>/K+ ATPase levels along with caspase-3 activation </plain></SENT>
<SENT sid="3" pm="."><plain>A marked reduction in <z:chebi fb="0" ids="16856">glutathione</z:chebi>, <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase, <z:chebi fb="0" ids="16856">glutathione</z:chebi> reductase, <z:chebi fb="0" ids="16856">glutathione</z:chebi>-S-transferase, <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase and catalase levels along with increase in the levels of <z:chebi fb="0" ids="33202">thiobarbituric acids</z:chebi> (TBARS) were also observed in rat myocardium </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, DNA laddering observed on <z:chebi fb="2" ids="2511">agarose</z:chebi> gel electrophoresis and cardiac histopathology study further supplemented myocardial <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Pre-treatment with GPC significantly reduced DOX-induced cardiac toxicity, including improvement of hemodynamic variables and heart weight to body weight ratio, decreased serum <z:chebi fb="0" ids="29108">Ca2+</z:chebi> level and LDH levels, myocardial caspase-3 levels, increased <z:chebi fb="1" ids="29101">Na+</z:chebi>/K+ ATPase levels and decreased myocardial TBARS levels and elevated <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzymes as compared to pathogenic control group </plain></SENT>
<SENT sid="6" pm="."><plain>Further, the anti-apoptotic effect of GPC was verified by prevention of internucleosomal DNA laddering on <z:chebi fb="2" ids="2511">agarose</z:chebi> gel electrophoresis and attenuation of histopathological perturbations by <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>These observations demonstrate that GPC might serve as a cardioprotective formulation in DOX-induced <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> in rats </plain></SENT>
</text></document>